Gusheng Tang

Gusheng Tang

Auto-generated profile, based on publicly available information

Gusheng Tang

Changhai Hospital

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2009 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
HXHuang Xiangyan
Huang Xiangyan
YQYanghua Qin
Yanghua Qin
PZPeng Zhang
Peng Zhang
GTGusheng Tang
Gusheng Tang
QSQingfen Shi
Qingfen Shi
QSQian Shen
Qian Shen

24 November 2017 in Oncology Letters
Verified
Journal Article
Open access
PDF file
WGWEI GAO
WEI GAO
MWMeihong Wu
Meihong Wu
NWNing Wang
Ning Wang
Yingyi ZhangYingyi Zhang
Yingyi Zhang
JHJing Hua
Jing Hua
YWYajie Wang
Yajie Wang
Nuclear respiratory factor‑1 (Nrf1) and mitochondrial transcription factor A (TFAM) are involved in the regulation of a variety of mitochondrial functional genes, which are associated with decreased sensitivity of tumor cells to chemotherapy. However, the expression status of Nrf1 and TFAM, as well as their clinical significance in breast cancer, is unknown. In the present study, tumor tissues and corresponding adjacent normal tissues were collected from 336 patients with breast cancer, and Nrf1 and TFAM expression was analyzed by immunohistochemistry using a tissue microarray. Expression of Nrf1 and TFAM was significantly increased in breast cancer tissue compared with adjacent normal tissues. In addition, patients positive for Nrf1 or TFAM had a poorer clinical prognosis than patients who were negative, and those positive for Nrf1 and TFAM had the shortest survival time. These results suggest that Nrf1 and TFAM are potential biomarkers for the determination of individualized therapy and the prognosis of breast cancer, and molecular targeting of Nrf1 and TFAM is a promising strategy for the sensitization of breast cancer cells to chemotherapeutics.

8 April 2016 in International Journal of Molecular Medicine
Verified
Journal Article
Open access
NLNan Liu
Nan Liu
CWChen Wang
Chen Wang
LWLibing Wang
Libing Wang
LGLei Gao
Lei Gao
HCHui Cheng
Hui Cheng
JWJianmin Wang
Jianmin Wang
Acute myeloid leukemia (AML) is an aggressive clonal malignancy of hematopoietic progenitor cells with a poor clinical outcome. The resistance of leukemia cells to contemporary chemotherapy is one of the most formidable obstacles to treating AML. Combining valproic acid (VPA) with other anti-leukemic agents has previously been noted as a useful and necessary strategy which can be used to specifically induce anticancer gene expression. In the present study, we demonstrated the synergistic antileukemic activities between VPA and cytarabine (Ara‑C) in a retrovirus-mediated murine model with MLL-AF9 leukemia, three leukemia cell lines (THP-1, K562 and HL-60) and seven primary human AML samples. Using RT-qPCR, we noted that the combination of VPA and Ara‑C significantly upregulated Bax expression and led to the arrest of leukemia cell proliferation, sub-G1 DNA accumulation and cell apoptosis, as demonstrated by flow cytometric analysis. Significantly, further experiments revealed that knockdown of Bax expression prevented VPA and Ara‑C‑induced cell apoptosis in THP-1 cells. The results of our present study demonstrated the synergistic antileukemic effect of combined VPA and Ara‑C treatment in AML, and thus we suggest that VPA be used an alternative treatment for AML.

12 March 2024 in Research Square
Verified
Preprint
Open access
PDF file
HCHui Cheng
Hui Cheng
JDJing Ding
Jing Ding
JWJuan Wang
Juan Wang
YXYujun Xiao
Yujun Xiao
XJXinyi Jin
Xinyi Jin
GTGusheng Tang
Gusheng Tang
Background: The presence of the RUNX1::RUNX1T1 fusion gene in patients diagnosed with acute myeloid leukemia (AML) subtype is often indicated by distinctive morphological features in myeloblasts from bone marrow (BM) smears. This study aims to evaluate the capacity of artificial intelligence (AI) to identify specific genetic abnormalities based solely on morphological characteristics. The intent is to investigate a non-invasive, cost-effective, and efficient preliminary screening method prior to the application of molecular biological assays. Methods: This multicenter trial included 205 patients diagnosed with AML, of which 75 were AML with RUNX1::RUNX1T1 fusion. A dataset of 65,039 myeloblasts images collected from the BM smears of these patients was compiled for model training, testing, and validation. The study also undertook a comparative analysis of the discrepancies between manual microscopy and AI-based identification. Results: The model demonstrated proficiency in adapting to varied clinical scenarios by applying two different threshold values. Under the threshold of 0.59, the testing and validation cohorts showed sensitivities of 92.86% and 95.65%, with corresponding accuracies of 87.04% and 71.88%. Conversely, by setting the threshold at 0.88, specificities of 92.31% and 92.68% were achieved, along with accuracies of 88.89% and 90.63%. Regardless of the threshold, the AI model consistently outperformed manual microscopy (average accuracy: 50.00%). Conclusion: The model demonstrates a significant capability to discern underlying RUNX1::RUNX1T1 genetic alterations from the morphological attributes of BM nucleated cells with a precision surpassing human observation. This providing a valuable tool highlights its potential for enhancing diagnostic efficiency in clinical practice.

1 October 2026 in Genes & Diseases
Verified
Journal Article
Open access
ZSZhiqiang Song
Zhiqiang Song
ZFZhendong Fu
Zhendong Fu
YCYuyan Chen
Yuyan Chen
DZDongliang Zhang
Dongliang Zhang
YGYuke Geng
Yuke Geng
JYJianmin Yang
Jianmin Yang

18 March 2020 in Cytometry Part B: Clinical Cytometry
Verified
Journal Article
Open access
PDF file
FBFrederic Boston
Frederic Boston
JGJan W. Gratama
Jan W. Gratama
BSBenjamin E. J. Spurgeon
Benjamin E. J. Spurgeon
KNKhalid M. Naseem
Khalid M. Naseem
GBGregory K Behbehani
Gregory K Behbehani
GTGusheng Tang
Gusheng Tang
Cytometry Part B: Clinical Cytometry focuses on the development and applications of cellular system analysis and array based technologies as applied to clinical practice and translational research. This journal also covers relevant techniques such as flow cytometry, image cytometry, beadbased and slide-based array analyses, as well as other cell-based spectroscopic analyses. In addition, Clinical Cytometry publishes clinical and translational investigations that identify and validate the features and molecules important in diagnosis, prognosis, and therapeutic management of patients